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ART ICLE Open Ac ce s s
XK-related protein 5 (XKR5) is a novel
negative regulator of KIT/D816V-mediated
transformation
Jianmin Sun1,2,3, Tine Thingholm2,3,4, Peter Højrup4 and Lars Rönnstrand 2,3,5
Abstract
In order to investigate the molecular mechanisms by which the oncogenic mutant KIT/D816V causes transformation of
cells, we investigated proteins that selectively bind KIT/D816V, but not wild-type KIT, as potential mediators of
transformation. By mass spectrometry several proteins were identiﬁed, among them a previously uncharacterized
protein denoted XKR5 (XK-related protein 5), which is related to the X Kell blood group proteins. We could
demonstrate that interaction between XKR5 and KIT/D816V leads to phosphorylation of XKR5 at Tyr 369, Tyr487, and
Tyr 543. Tyrosine phosphorylated XKR5 acts as a negative regulator of KIT signaling, which leads to downregulation of
phosphorylation of ERK, AKT, and p38. This led to reduced proliferation and colony forming capacity in semi-solid
medium. Taken together, our data demonstrate that XKR5 is a novel type of negative regulator of KIT-mediated
transformation.
Introduction
The stem cell factor receptor, KIT, is a receptor tyrosine
kinase that has been found to be mutated and con-
stitutively active in a number of human malignancies,
including mast cell leukemia, core binding factor acute
myeloid leukemia, gastrointestinal stromal tumors
(GISTs), malignant melanoma and testicular carcinoma
(for review, see ref.1). One of the most commonly found
mutations, D816V, is located in the activation loop of the
kinase domain. The exact mechanism by which it causes
transformation is not fully understood. We and others
have shown that KIT/D816V is not only constitutively
active, but also has the capacity to phosphorylate other
proteins than wild-type KIT2–4. In an attempt to gain
further insight into the molecular pathways utilized by the
KIT/D816V mutant, we immunoprecipitated either wild-
type KIT or KIT/D816V from transfected Ba/F3 cells and
analyzed the co-immunoprecipitating proteins. One of the
proteins associating with KIT/D816V, but not with wild-
type KIT, was a hitherto uncharacterized protein, XKR5
(XK-related protein 5). In this paper we demonstrate that
XKR5 is a novel negative regulator of KIT signaling that
inhibits KIT/D816V-induced transformation.
Results
XKR5 binds to the oncogenic mutant KIT/D816V but not to
wild-type KIT
It has been reported that the most commonly found
activating KIT mutation, D816V, is not only constitutively
active in the absence of ligand stimulation, but it also has
gained an altered kinase speciﬁcity and therefore activates
additional signaling pathways apart from those activated
by wild-type KIT5. In order to study which additional
signaling pathways that are activated by KIT/D816V, we
puriﬁed KIT/D816V and its associated proteins by large
scale immunoprecipitation from Ba/F3 cells expressing
KIT/D816V. As a control, cells expressing wild-type KIT
were used. We observed many additional bands in
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samples immunoprecipitated from KIT/D816V-expres-
sing Ba/F3 cells compared to samples immunoprecipi-
tated from wild-type KIT expressing cells (Fig. 1). This
suggests that KIT/D816V utilizes additional proteins,
apart from those used by wild-type KIT, to mediate its
signals into the cell. The additional bands were excised
and analyzed by mass spectroscopy. Several previously
identiﬁed KIT binders were found (e.g., PI3-kinase) but
also novel hitherto unknown KIT interactors. In order to
verify our ﬁndings, we co-expressed several of these
proteins in COS1 cells together with KIT/D816V and
found that one of the proteins, that we could verify to
associate with KIT/D816V, was the protein XKR5 (data
not shown). As shown in Fig. 2a, both murine and human
XKR5 were able to pull down KIT/D816V but not wild-
type KIT, suggesting that XKR5 selectively associates with
KIT/D816V but not with wild-type KIT. Colocalization of
KIT/D816V with both murine and human XKR5 was
demonstrated with confocal microscopy, while wild-type
KIT did not show any co-localization with XKR5 (Fig. 2b).
Thus, this further veriﬁes that XKR5 is an interaction
partner of KIT/D816V but not of wild-type KIT.
XKR5 is highly expressed in hematopoietic cells
XKR5 is a novel, hitherto uncharacterized protein and
its biological role is unknown. In order to analyze the
expression of XKR5 in different tissues and whether it is
expressed in tissues in which KIT/D816V often is
expressed, we analyzed the gene expression dataset
GSE10246. Interestingly, we observed high XKR5
expression in hematopoietic cells compared to other tis-
sues (Fig. 3a). In addition, Western blot analysis of
hematopoietic cells showed strong expression of XKR5
(Fig. 3b). Since the KIT/D816V mutation has been
reported in several hematological malignancies, including
mastocytosis and core binding factor acute myeloid leu-
kemia (CBF AML), this suggests that the interaction
found is relevant for KIT function.
XKR5 is phosphorylated by KIT/D816V on Tyr 369, Tyr487,
and Tyr 543
KIT/D816V differs from wild-type KIT in several
aspects. While both are active tyrosine kinases, they dis-
play different substrate speciﬁcity5. We have recently
reported that KIT/D816V, but not ligand stimulated wild-
type KIT, induces tyrosine phosphorylation of p110delta
and the adaptor protein SLAP, and that the phosphor-
ylation of these proteins contribute to KIT/D816V-
mediated cell transformation2,4. To know whether KIT/
D816V also holds similar properties to XKR5, we ﬁrst
checked tyrosine phosphorylation of XKR5 using a pan-
phosphotyrosine antibody, 4G10. The results show that
both murine and human XKR5 are tyrosine phosphory-
lated by KIT/D816V but not by wild-type KIT (Fig. 2a).
Since both murine and human XKR5 were tyrosine
phosphorylated, we speculated that the tyrosine phos-
phorylation sites in the two species are likely to be con-
served. Sequence alignment of the XKR5 sequences
demonstrated that three tyrosine residues in the intra-
cellular domain of XKR5 are conserved between murine
and human XKR5 including Tyr369, Tyr 487, and Tyr 543
(Fig. 4a). We generated a panel of XKR5 Y-to-F mutants
of these sites and observed that each single mutation of
those three sites reduced tyrosine phosphorylation of
XKR5 and that the triple mutation almost completely
eliminated tyrosine phosphorylation (Fig. 4b). Therefore,
we suggest that Tyr369, Tyr 487, and Tyr 543 in XKR5 are
phosphorylated by KIT/D816V. Furthermore, we showed
that phosphorylation of XKR5 can be blocked by the KIT/
D816V inhibitor dasatinib (Fig. 4c).
XKR5 is phosphorylated by D816X mutants of KIT but not
by other oncogenic KIT mutants
KIT mutations commonly occur in GISTs, mastocy-
tosis, CBF AML, and less commonly in melanoma, germ
cell tumors and other malignancies1,6. The D816V
mutation in exon 17 of KIT, which encodes the activation
loop of the kinase domain, is the most commonly
occurring KIT mutation in mastocytosis and CBF AML.
In GISTs, mutations in KIT are usually localized to exon
11, which encodes the juxtamembrane region, and less
often to exon 9, 13 and 17. To understand whether
phosphorylation and association of XKR5 is common to
Fig. 1 Identiﬁcation of XKR5 as a protein selectively binding to
KIT/D816V but not wild-type KIT. Nine hundred million Ba/F3 cells
expressing either wild-type KIT or KIT/D816V were starved in medium
without serum and IL-3 for 4 h followed by stimulation with SCF for
2 min. Cells were washed with PBS and lysed in lysis buffer. The lysates
were centrifuged and supernatants were incubated with a KIT
antibody for 1 h at 4 °C followed by incubation with protein G Dyna
beads for 30 min at 4 °C. The immunoprecipitates were washed in lysis
buffer, boiled for 5 min in SDS-PAGE sample buffer and separated by
SDS-PAGE followed by staining with Coomassie Brilliant Blue. The
band labeled “XKR5” was analyzed by mass spectrometry and found to
be identical to XKR5
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Fig. 2 XKR5 binds to and colocalizes with KIT/D816V but not with wild-type KIT. a COS1 cells were co-transfected with FLAG-tagged XKR5 and
wild-type KIT or KIT/D816V. 48 h after transfection, cells were stimulated with SCF for 2 min, lysed and immunoprecipitated with antibodies against
FLAG-tag (for the detection of XKR5) or KIT antibody, respectively. After separation by SDS-PAGE and transfer to PVDF membranes, the membranes
were probed with either KIT antibodies or phosphotyrosine antibodies to visualized phosphorylated proteins. b The localization of XKR5 and KIT was
visualized by confocal microscopy. KIT was stained with a PE-conjugated antibody and XKR5-FLAG was stained with Alexa Fluor 647-conjugated FLAG
antibody. The co-localization of XKR5 and KIT (three experiments) was quantiﬁed
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Fig. 3 Tissue distribution of XKR5 expression. a Gene expression dataset GSE10246 was downloaded from PubMed and the expression of XKR5 in
various tissues was extracted and analyzed by Graphpad. b 32D, Ba/F3, FDC-P1, and P815 cells were lysed. The total cell lysates were separated by
SDS-PAGE, electrotransferred and probed with an antibody against XKR5
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Fig. 4 Tyrosines 369, 487, and 543 are conserved between murine and human XKR5 and essential for the function of XKR5. a Alignment of
the protein sequence of human and murine XKR5 show that Tyr369, Tyr 487, and Tyr 543 are conserved between murine and human XKR5. b
COS1 cells were transfected with KIT/D816V and wild-type XKR5 or triple Y-to-F mutant of XKR5. Cells were lysed and immunoprecipitated with KIT or
FLAG antibodies (to detect XKR5), followed by SDS-PAGE and western blotting analysis. c COS1 cells were co-transfected with KIT/D816V and wild-
type XKR5, and incubated with the kinase inhibitor dasatinib (2 nM) for 5 h. Cells were lysed and immunoprecipitated with KIT or FLAG antibodies, to
detect XKR5, followed by SDS-PAGE and western blotting analysis. d COS1 cells were co-transfected with XKR5 and either wild-type KIT or KIT
mutants. Cells were lysed and immunoprecipitated with KIT or FLAG antibodies (to detect XKR5), followed by SDS-PAGE and western blotting
analysis. e COS1 cells were co-transfected with XKR5 and either wild-type KIT, KIT/D816V, or KIT/D816V/Y568F/Y570F (lacking SRC binding sites). Cells
were lysed and immunoprecipitated with KIT or FLAG antibodies (to detect XKR5), followed by SDS-PAGE and western blotting analysis
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all activating KIT mutants, we co-expressed XKR5 with
KIT mutated at exon 9, 11, and 17, as well as other D816X
mutants, apart from D816V. Immunoprecipitation of
XKR5 demonstrated that all KIT D816X mutants can
bind to and phosphorylate XKR5, whereas the other KIT
mutants neither associated with nor phosphorylated
XKR5 (Fig. 4d). Thus, association of KIT with XKR5 is
limited to the D816X mutants.
The tyrosine phosphorylation of XKR5 is not dependent on
SRC family kinases
SRC family kinases play a crucial role in the activation of
wild-type KIT7 while KIT/D816V gains SRC-like kinase
activity and becomes independent of SRC family kinases
for the activation of KIT/D816V and its downstream
signaling5. Tyr 568 in KIT is the binding site of SRC
family kinases and the binding can be further enhanced by
phosphorylation of Tyr 5708. Co-expression of XKR5 with
KIT/D816V carrying mutations of the SRC family kinases
binding sites did not block tyrosine phosphorylation of
XKR5 nor the association between XKR5 and KIT/D816V
(Fig. 4e), indicating that SRC family kinases are not
necessary for phosphorylation of XKR5 by KIT/D816V.
Tyrosine phosphorylation of XKR5 leads to inhibition of
signal transduction pathways downstream of KIT/D816V
In order to investigate the role of XKR5 in KIT/D816V
signaling, we examined whether XKR5 regulates KIT
activation. Co-expression of KIT and XKR5 showed that
the activation of both wild-type KIT and KIT/D816V
remains unaffected by the presence or absence of XKR5
(Fig. 5a,b), suggesting that it, despite associating with KIT,
does not inﬂuence its kinase activity.
To further investigate whether XKR5 regulates signal
transduction pathways downstream of KIT/D816V, the
murine mastocytoma cell line P815, which endogenously
expresses KIT/D814V (corresponding to KIT/D816V in
humans), was used as cell model. Immunoprecipitation
with XKR5 antibody showed that KIT/D814V binds to
XKR5 in P815 cells (Fig. 5c). The expression of XKR5 was
knocked down by three different shRNAs and the one that
gave best knockdown was used for further experiments
(Fig. 5d). Knockdown of XKR5 in P815 cells enhanced
phosphorylation of the three downstream signaling
molecules AKT, ERK, and p38 that are important for cell
survival and proliferation (Fig. 5e). In line with that,
overexpression of XKR5 inhibited phosphorylation of
AKT, ERK and p38 (Fig. 5f), indicating that XKR5 is a
negative regulator of KIT/D816V signaling. To investigate
whether the inhibition of KIT/D816V signaling by XKR5
is mediated by the tyrosine phosphorylation of XKR5, the
triple mutant of XKR5 lacking the three phosphorylation
sites was overexpressed in P815 cells. As shown in Fig. 5f,
expression of the tyrosine mutant of XKR5 enhanced
phosphorylation of AKT, ERK, and p38, suggesting that
the inhibition of KIT/D816V signaling by XKR5 is
mediated through tyrosine phosphorylation of XKR5.
Tyrosine phosphorylation of XKR5 leads to inhibition of
KIT/D816V-mediated cell proliferation and colony
formation in semi-solid medium
Due to the inhibitory role of XKR5 on the activation of
AKT, ERK, and p38, we further examined whether XKR5
also is a negative regulator of KIT/D816V-mediated cell
transformation. By ﬂow cytometry, we found that neither
knockdown nor overexpression of XKR5 changed the
survival of P815 cells, even in the presence of KIT inhi-
bitor PKC412 (Fig. 6a), while knockdown of XKR5
enhanced the proliferation and overexpression of XKR5
inhibited proliferation of P815 cells. Furthermore, over-
expression of the triple Y-to-F mutant of XKR5 enhanced
proliferation of P815 cells (Fig. 6b). Taken together, these
data suggest that XKR5 is a negative regulator of KIT/
D816V-mediated proliferation and that it is mediated
through tyrosine phosphorylation of XKR5. In a similar
fashion, knockdown of XKR5 enhanced colony formation
of P815 cells in semi-solid medium, while overexpression
of XKR5 suppressed colony formation. Similar to the
effect on cell proliferation, the effect was dependent on
tyrosine phosphorylation of XKR5 (Fig. 6c, d). Taken
together, these results suggest that XKR5 is a novel
phosphorylation-dependent negative regulator of KIT/
D816V-mediated cell transformation.
Discussion
Mutated constitutively active receptor tyrosine kinases
are commonly found in human malignancies. One of the
most common mutants of KIT in human tumors is the
KIT/D816V mutant. It is characterized by a high con-
stitutive kinase activity, but also by an altered substrate
speciﬁcity3,5. Together with the fact that KIT/D816V is
trapped in the Golgi and signals from there9, it makes it
likely that several signaling proteins are activated by KIT/
D816V but not by wild-type KIT. We have so far identi-
ﬁed p110 delta and SLAP as proteins phosphorylated only
by KIT/D816V and not by wild-type KIT2,4. In order to
identify additional KIT/D816V-speciﬁc substrates, we
immunoprecipitated KIT from KIT/D816V-expressing
Ba/F3 cells, ran out the immunoprecipitates on SDS-
PAGE and stained with Coomassie Brilliant Blue. Bands of
interest were excised and analyzed by mass spectrometry.
Several proteins were identiﬁed, of which the band iden-
tiﬁed as XKR5 was the most prominent.
XKR5 is a by and large uncharacterized protein
belonging to the XKR group of proteins that are related to
the Kell blood group antigen. The family of proteins
consists of 9 different family members, XKR1-9. They are
predicted to be transmembrane proteins with six
Sun et al. Oncogenesis  (2018) 7:48 Page 6 of 11
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Fig. 5 (See legend on next page.)
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transmembrane regions10. XKR1 has been shown to reg-
ulate cell volume by transport of divalent cations11. Other
members, such as XKR4, XKR8, and XKR9, are involved
in facilitation of apoptotic phosphatidylserine exposure10.
One recent genome wide association study correlated the
expression of XKR9 with erythrocyte cadmium12, sug-
gesting a possible role in cadmium absorption and/or
metabolism. It is likely that all members are involved in
some type of transportation across the plasma membrane.
Interaction of XKR5 with KIT leads to phosphorylation
of XKR5 on Tyr 369, Tyr487, and Tyr 543. Tyrosine
phosphorylated XKR5 acts as a negative regulator of KIT
signaling, which leads to downregulation of phosphor-
ylation of ERK, AKT, and p38. The biological effects are
reduced proliferation and reduced colony forming capa-
city in semi-solid medium. The mechanism by which
XKR5 exerts its effect is not known. It is likely that the
three phosphorylation sites constitute docking sites for
proteins involved in signaling downstream of XKR5.
However, the sequence surrounding the tyrosine residues
do not give any obvious hint as to which proteins might
be involved. Future studies will look into the details of
how XKR5 exerts its negative effect on signaling.
Transformation by oncogenic mutants of receptor tyr-
osine kinases involves the activation of a number of signal
transduction molecules, both those that mediate a positive
signal but also an activation of proteins that are negative
regulators. In leukemic cells transformed by the related
RTK FLT3, we have previously demonstrated that acti-
vation of FLT3 strongly induces SOCS6 expression13. It
might seem counter intuitive to think that the upregula-
tion of a negative regulator could be important for
transformation, but there are several cases where too high
activity of a receptor tyrosine kinase has been shown to
induce apoptosis, rather than transformation. E.g.,
A431 cells that overexpress the EGF receptor respond to
EGF stimulation by induction of apoptosis14. Further-
more, ectopic expression of FLT3 has been shown to
induce apoptosis in certain cell types15. Thus, engagement
of a negative regulator such as XKR5 could be important
for transformation.
Taken together, our data demonstrate that XKR5 is a
novel type of negative regulator of KIT mediated trans-
formation that inﬂuences AKT, ERK, and p38 signaling, as
well as cell proliferation and transformation but not
apoptosis.
Materials and Methods
Cytokines and antibodies
Recombinant human stem cell factor (SCF) was from
Prospec Tany, Israel. The rabbit antibody KitC1 that
recognizes the C-terminal tail of human KIT was puriﬁed
as described16. The antibody against murine XKR5 was
generated by immunizing rabbit with a synthetic peptide
corresponding to the C-terminus of XKR5
(CHHAAVGVWVSLPQ) conjugated to KLH and afﬁnity
puriﬁed. Antibodies against AKT (SC8312), ERK
(SC292838) and pERK (SC16982-R) were from Santa
Cruz Biotechnology. pAKT antibody (cat. no. 2118-1) was
from Epitomics. Phosphotyrosine antibody 4G10 (cat. no.
05-321) was from Millipore. pp38 (cat. no. 612289) and
p38 antibodies (cat. no. 612169) were from BD Bios-
ciences. β-actin (cat. no. A1978) and FLAG antibodies
(cat. no. F1804) were from Sigma-Aldrich. PE labeled KIT
antibody (104D2; cat. no. 313204 was from BioLegend.
Horseradish peroxidase conjugated anti-rabbit (cat. no.
31460) and anti-mouse (cat. no. 31430) secondary anti-
bodies were from Life Technologies.
Kits and reagents
ShRNAs were from Origene. QuikChange mutagenesis
kit was from Agilent Technologies. Annexin V-PE apop-
tosis detection kit was from BD Biosciences. Transfection
reagent Lipofectamine 2000, Coomassie Blue and protein
G Dyna beads for immunoprecipitation were from Life
Technologies. Chemiluminescent HRP substrate was
from Millipore. Aprotinin and phenylmethylsulfonyl
ﬂuoride were from Sigma-Aldrich. All the reagents
(see ﬁgure on previous page)
Fig. 5 XKR5 does not inﬂuence the kinase activity of KIT but is a negative regulator of the downstream signaling molecules ERK, AKT, and
p38. a COS1 cells were co-transfected with wild-type KIT and various amounts of XKR5. Cells were lysed and immunoprecipitated with KIT or FLAG
antibodies, followed by SDS-PAGE and western blotting analysis. b COS1 cells were co-transfected with KIT/D816V and various amounts of XKR5. Cells
were lysed and immunoprecipitated with KIT or FLAG antibodies, followed by SDS-PAGE and western blotting analysis. c P815 cells were lysed and
immunoprecipitated with XKR5 antibody or rabbit IgG, followed by SDS-PAGE and western blotting analysis. d P815 cells were stably transfected with
four different shRNAs targeting XKR5. Cells were lysed and immunoprecipitated with XKR5 antibodies, followed by SDS-PAGE and western blotting
analysis to detect the level of XKR5 protein. e P815 cells were stably transfected with shRNA targeting XKR5 or control shRNA. Cells were lysed,
followed by SDS-PAGE and western blotting analysis using antibodies against phosphoAKT, phosphoERK and phosphop38 and the corresponding
non-phosphorylated proteins, respectively. f P815 cells were transfected with wild-type XKR5 or the Y-to-F triple mutant of XKR5. Cells were lysed and
total cell lysates were probed with antibodies against phosphoAKT, phosphoERK and phosphop38 and the corresponding non-phosphorylated
proteins, respectively. In parallel, lysates were imunoprecipitated with KIT antibody followed by SDS-PAGE and western blotting analysis
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Fig. 6 XKR5 does not inﬂuence survival of P815 cells, but is a negative regulator of both proliferation and the capacity to form colonies in
semi-solid medium. P815 cells were seeded in 24-well plates at a density of 70,000 cells/ml and incubated for two days. a Cells were stained with
cell apoptosis detection kit and analyzed by ﬂow cytometry to detect the level of cell survival. b The number of live cells was counted by trypan blue
exclusion to measure the cell proliferation. c P815 cells were mixed with semi-solid colony assay medium MethoCult® M3231 and 100 cells were
seeded in 24-well plates. After incubation for 6 days, colonies were counted. Statistical signiﬁcance was calculated by t test. d Photographs of
colonies after 6 days of incubation, the scale bar indicates 100 μm
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and kits were used according to the manufacturer’s
instructions.
Cell culture
Ba/F3 cells (DSMZ, Braunschweig, Germany) were
grown in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum, 100 units/ml peni-
cillin and 100 µg/ml streptomycin, and 10 ng/ml recom-
binant murine IL-3 as previously described17. The virus
packaging cell line EcoPack and the mastocytoma cell line
P815 were grown in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum, 100 units/ml
penicillin and 100 µg/ml streptomycin. FDC-P1 cells were
grown in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum, 100 units/ml peni-
cillin and 100 µg/ml streptomycin, and 10 ng/ml
recombinant murine IL-3. In order to establish Ba/F3 cell
lines expressing KIT, EcoPack cells were transfected with
KIT constructs in pMSCVpuro vector. Supernatants were
collected to infect Ba/F3 cells followed by 2-weeks selec-
tion in 1.2 μg/ml puromycin. Expression of KIT was
conﬁrmed by ﬂow cytometry and immunoblotting. KIT
expressing Ba/F3 cells were grown in the same medium as
untransfected Ba/F3 cells. All cells were regularly tested
for mycoplasma.
Large scale puriﬁcation of KIT and associated proteins
900 million Ba/F3 cells expressing wild-type KIT or
KIT/D816V were starved in serum-free medium in the
absence of IL-3 for 4 h followed by SCF stimulation
(100 ng/ml) for 2 min. Cells were washed once in ice-cold
PBS and lysed in 30 ml lysis buffer containing 1% Triton
X-100, 25 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA,
10% glycerol, 2 µg/ml aprotinin, 1 mM Na3VO4 and 1mM
phenylmethylsulfonyl ﬂuoride. The lysates were cen-
trifuged at 14,000 × g for 15 min at 4 °C and supernatants
were incubated end-over-end with 10 μg KitC1 antibody
for 1 h followed by incubation with 100 μl protein G Dyna
beads for 30min at 4 °C. The immunoprecipitates were
washed three times in lysis buffer, boiled for 5 min in
SDS-PAGE sample buffer and separated by SDS-PAGE
followed by staining with Coomassie Blue. Band of
interest were excised and identiﬁed by mass spectrometry.
Mass spectrometry
The gel bands of interest were excised from the gel, and
subjected to in-gel digestion by trypsin (sequencing grade;
Promega) as described previously18. The resulting pep-
tides were puriﬁed using TiO2 chromatography
19,20 and
desalted20 prior to mass spectrometry (MS) analysis. The
puriﬁed peptides were applied onto an EASY nano-LC
system (Proxeon Biosystems, Odense, Denmark), and
analyzed using a LTQ Orbitrap XL mass spectrometer
(Thermo Electron, Bremen, Germany). The peptides were
concentrated on a 1.0-cm precolumn (75-μm inner dia-
meter, 360-μm outer diameter, ReproSil-Pur C18 AQ 3
μm (Dr. Maisch, Ammerbuch-Entringen, Germany)) and
eluted from the precolumn using a gradient from 100%
phase A (0.5% acetic acid aqueous solution) to 40% phase
B (0.5% acetic acid, 80% acetonitrile) at 200 nl min−1
directly onto an 8-cm analytical column (50-μm inner
diameter, 360-μm outer diameter, ReproSil-Pur C18 AQ 3
μm). The instrument was operated in a data-dependent
mode automatically switching between MS, MS2, and
pdMS3 21. The data were processed using Proteome Dis-
coverer, beta-version 1.1.0.228. The ﬁles were subse-
quently submitted to an in-house MASCOT server
(version 2.2.05) (Matrix Science Ltd., London, U.K.) for
database searching through the Proteome Discoverer
program. The data were searched against the Swiss-Prot
mouse sequence database. The search was performed
choosing trypsin as speciﬁc enzyme. A maximum of 2
missed cleavages were allowed. Carbamidomethyl (C) was
chosen as ﬁxed modiﬁcation. As variable modiﬁcations
Oxidation (M) were chosen. The data were searched with
a peptide mass tolerance of 10 p.p.m. and a fragment mass
tolerance of 1.1Da. Finally, the data were searched against
the decoy database to calculate a false discovery rate
(FDR) of 1 and 5% using the Proteome Discoverer pro-
gram. Protein grouping was performed in the Proteome
Discoverer program.
Analysis of XKR5 expression in tissues
GEO dataset GSE10246 was downloaded from PubMed
and the expression of XKR5 in various tissues was
extracted and analyzed by the software Graphpad.
Cell stimulation, immunoprecipitation, and western
blotting
Cell stimulation, immunoprecipitation, and western
blotting was performed as previously described4.
Co-localization of XKR5 and KIT
COS1 cells were co-transfected with FLAG-tagged
XKR5 and wild-type KIT or KIT/D816V. 48 h after
transfection, cells were stimulated with SCF for 2 min.
Cells were then ﬁxed in 4% para-formaldehyde in PBS for
30min. Blocking and permeabilization was done by add-
ing a mixture of 0.5% Triton-X100 in PBS and 5% goat
serum. Cells were then stained with antibody and washed
before examination by confocal microscopy. Co-
localization was measured with CoLocalizer Pro
2.7.1 software.
Cell survival and proliferation assay
Cell survival and proliferation assay was performed as
described4.
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Colony formation assay
P815 cells were mixed with semi-solid colony assay
medium MethoCult® M3231 (Stem cell technologies)
according to the manufacturer’s instruction. Cell mixture
was seeded in 24-well plates. After incubation for 6 days,
colonies were counted and photographed. Statistical sig-
niﬁcance was calculated by t test.
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